secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001558370-24-015299
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Q3 net loss narrows to $9.0M; new Novartis capsid license; VY7523 SAD data H1 2025
--------------------------------------------------------------------------------

- Q3 collaboration revenue $24.6M (up from $4.6M YoY); net loss $9.0M vs $25.9M.
- Licensed TRACER capsid to Novartis for undisclosed rare neurologic target; $15M upfront, up to $305M milestones.
- Neurocrine partnership selected 3rd development candidate, triggering $3M milestone.
- VY7523 anti-tau antibody SAD trial enrollment complete; top-line safety/PK data expected H1 2025.
- Cash $345.4M at Sep 30; plus $18M received in Oct; runway into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000155837024015299/0001558370-24-015299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000155837024015299/vygr-20241112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer